Sunho Biologics Inc. has announced the resignation of its auditor, Deloitte Touche Tohmatsu, effective immediately due to a disagreement over the audit fee for the financial year ending December 31, 2025. The board of directors and the audit committee evaluated Deloitte's proposal alongside those from other firms, considering factors like industry experience and proposed fees. As Deloitte had not begun any audit work for the current fiscal year, the company expects no significant impact on its annual audit. Sunho Biologics is in the process of appointing a new auditor and will announce the appointment in due course. The company expressed appreciation for Deloitte's services during its tenure.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunho Biologics Inc. published the original content used to generate this news brief on September 15, 2025, and is solely responsible for the information contained therein.